Design, synthesis and biological evaluation of hypolipidemic compounds based on BRD4 inhibitor RVX-208
Authors:
- 1 August 2019
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (16) , 2168-2172
Abstract
No abstract availableKeywords
Funding Information
- Jiangsu Natural Science Foundation (BK20161438)
- Southeast University's Basic Research Business Fee Innovation Foundation (3207048416)
This publication has 27 references indexed in Scilit:
- Risk factors and therapies in vascular diseases: An umbrella review of updated systematic reviews and meta‐analysesJournal of Cellular Physiology, 2018
- Drug Discovery Targeting Bromodomain-Containing Protein 4Journal of Medicinal Chemistry, 2017
- Primary prevention with statins in cardiovascular diseases: A Saudi Arabian perspectiveJournal of the Saudi Heart Association, 2015
- A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient miceAtherosclerosis, 2014
- In vitro biosynthesis, isolation, and identification of predominant metabolites of 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one (RVX-208)European Journal of Medicinal Chemistry, 2013
- Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery DiseaseJACC, 2011
- ApoA-I mimetic peptides promote pre-β HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher doseBioorganic & Medicinal Chemistry, 2010
- Pan‐PPAR Agonists Based on the Resveratrol Scaffold: Biological Evaluation and Docking StudiesChemMedChem, 2010
- RVX-208JACC, 2010
- Low High-Density Lipoprotein Cholesterol and Increased Cardiovascular Disease Risk: An Analysis of Statin Clinical TrialsThe American Journal of Cardiology, 2009